---

Breast Cancer in a 38-Year-Old Woman - USMLE High-Yield Review

---

1. WHY A 38-YEAR-OLD IS HIGH RISK (Epidemiology)

• Lifetime risk = 1 in 8 for US females (to age 90)
• In young women (~40 years), TNBC and HER2-enriched subtypes are disproportionately common - they account for nearly half of breast cancers in young women but < 20% in older women
• Incidence of luminal (ER+) cancer peaks later in life; TNBC/HER2 subtypes plateau around age 40
• Young-onset breast cancer (≤40-45 yrs) strongly suggests hereditary etiology - up to ~10% of women with early-onset breast cancer carry a germline BRCA mutation
• BRCA testing is indicated if diagnosed at ≤45 years of age
• Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 4384
• Goldman-Cecil Medicine, p. 4151

---

2. GENETICS: BRCA1 AND BRCA2

• Sabiston Textbook of Surgery, p. 3010-3015
• Schwartz's Principles of Surgery

---

3. MOLECULAR SUBTYPES (Most USMLE-Tested)

• ER+/PR+ → tamoxifen (premenopausal), aromatase inhibitor (postmenopausal)
• HER2+ → trastuzumab (Herceptin), pertuzumab
• TNBC → chemotherapy + pembrolizumab (PD-1 checkpoint inhibitor) - markedly improved outcomes in 2022 trial
• Fischer's Mastery of Surgery, p. 1297-1310

---

4. TNM STAGING (AJCC 8th Ed) - Anatomic

• Goldman-Cecil Medicine, p. 4156-4187

---

5. PATHOLOGY: IN SITU vs. INVASIVE

DCIS (Ductal Carcinoma In Situ)

• No basement membrane invasion
• ~30% risk of progressing to invasive cancer in same breast
• Risk of metastasis is extremely small
• Treatment focuses on the breast, not axillary nodes typically

Invasive Ductal Carcinoma (IDC) - most common (~75%)

• Invades stroma
• Presents as a hard, irregular, fixed mass (stellate on imaging)
• Spreads via lymphatics to axillary LN → sentinel node biopsy

Invasive Lobular Carcinoma (ILC)

• E-cadherin negative (single-file "Indian file" pattern)
• Often ER+/PR+
• Bilateral in ~20%

Inflammatory Breast Cancer

• Skin edema (peau d'orange), erythema, warmth - NO discrete mass
• Due to dermal lymphatic invasion
• Stage IIIB by definition
• Worst prognosis among non-metastatic

---

6. RISK FACTORS (USMLE Mnemonic: DEARTH)

---

7. DIAGNOSIS AND WORKUP

1. Triple assessment: Clinical exam + Imaging + Biopsy (core needle preferred)
2. Imaging:
   • Mammography: ~10% of palpable cancers are mammography-negative
   • Ultrasound: helpful in dense breasts, young women
   • MRI: best for BRCA carriers, implant evaluation, extent of disease
3. Sentinel lymph node biopsy (SLNB): First step in axillary staging for clinically node-negative disease
4. Biomarker testing: ER, PR, HER2, Ki-67, grade - all mandatory for invasive cancer
5. Germline testing: BRCA1/2 panel - mandatory for this 38-year-old patient
6. Staging imaging (Stage III/IV only): CT chest/abdomen/pelvis + bone scan or PET scan

---

8. TREATMENT OVERVIEW

Surgery

• Lumpectomy + radiation = mastectomy in survival (NSABP B-06 trial) for early-stage disease
• Modified radical mastectomy: breast + axillary LN dissection
• Prophylactic contralateral mastectomy: considered in BRCA carriers

Radiation

• After lumpectomy (standard)
• After mastectomy if T3/T4 or ≥4 positive LN

Systemic Therapy

• Endocrine therapy (ER+):
  • Premenopausal (38 yo): Tamoxifen (SERM) ± ovarian suppression x 5-10 years
  • Tamoxifen side effects: endometrial cancer, DVT/PE, hot flashes
• HER2-targeted:
  • Trastuzumab (anti-HER2 antibody) + chemotherapy
  • New: trastuzumab deruxtecan (T-DXd) - effective even in HER2-low disease
• Chemotherapy (AC-T or CMF):
  • Anthracycline (doxorubicin) + cyclophosphamide → paclitaxel
• TNBC:
  • Chemotherapy + pembrolizumab (checkpoint inhibitor) - major survival benefit (2022 clinical trial)
  • PARP inhibitors (olaparib, talazoparib) if BRCA mutation present

Neoadjuvant Therapy

• Given before surgery to downstage tumor
• Pathologic complete response (pCR) = excellent prognosis marker

---

9. PROGNOSIS

• Young age is an independent adverse prognostic factor (recent meta-analysis, PMID: 41029018, 2025)
• Higher rate of TNBC and HER2-enriched subtypes in young women
• Higher risk of pregnancy-associated breast cancer complications (PMID: 41892835, 2026 systematic review)
• Fertility preservation counseling should be offered before chemotherapy
• Consider ovarian suppression to preserve fertility during treatment

5-Year Survival by Stage (approximate)

---

10. SPECIAL USMLE SCENARIOS

---

Quick Memory Anchor for USMLE

• BRCA1 → Chromosome 17 → Higher ovarian risk (44%)
• BRCA2 → Chromosome 13 → Higher pancreatic/male breast risk

• Luminal A: best prognosis
• TNBC: worst prognosis BUT pembrolizumab now helps significantly

• Age 38 (premenopausal) → Tamoxifen
• Postmenopausal → Aromatase inhibitor (anastrozole, letrozole, exemestane)

Recent Evidence Update: A 2025 meta-analysis (PMID: 41029018) confirmed young age (< 40) is an independent poor prognostic factor for breast cancer survival, reinforcing the need for aggressive workup and counseling in this patient age group.

---

Brain Metastasis - USMLE High-Yield Review

---

MRI: Multiple Brain Metastases from Breast Carcinoma

---

1. EPIDEMIOLOGY (Most Tested)

• Brain metastases are the most common intracranial tumors in adults - far more common than primary brain tumors
• ~25% of all cancer patients die with intracranial metastases
• About 3-8% of cancer patients develop leptomeningeal/neoplastic meningitis

Primary Cancers Ranked by Frequency of Brain Mets:

• Goldman-Cecil Medicine, p. 4033
• Harrison's Principles, p. 401

---

2. PATHOPHYSIOLOGY & LOCATION

Why Grey-White Junction?

• Arterioles narrow abruptly at the cortical grey-white junction
• Tumor emboli get trapped at this junction → implant and grow
• Classic USMLE imaging clue: lesions at grey-white junction with surrounding edema

Mechanism of Symptoms:

1. Vasogenic edema - tumor disrupts blood-brain barrier → protein-rich fluid leaks → surrounds lesion
2. Mass effect - displaces brain tissue
3. Hydrocephalus - CSF obstruction if near ventricles
4. Herniation - uncal, central, tonsillar depending on location
5. Seizures - cortical irritation
6. Hemorrhage - especially melanoma, RCC, thyroid, choriocarcinoma

---

3. CLINICAL FEATURES

Cushing Triad (late, ominous sign):

• Hypertension + Bradycardia + Irregular respirations = impending herniation

---

4. HEMORRHAGIC METASTASES (High-Yield)

• Melanoma (#1 propensity)
• Renal cell carcinoma
• Thyroid carcinoma
• Choriocarcinoma
• Lung (most common overall because it's so frequent)

---

5. DIAGNOSIS

Imaging Hierarchy:

MRI Appearance:

• Ring-enhancing lesion(s) with surrounding low-density (dark) vasogenic edema
• Located at grey-white junction
• Often multiple (single in ~30-40%)
• Gadolinium enhancement = disrupted BBB

Ring-Enhancing Lesion DDx (USMLE):

---

6. TREATMENT

Step 1: Immediate Symptom Control

• Dexamethasone 8-12 mg/day - first-line for symptomatic brain mets
  • Reduces vasogenic edema rapidly (hours)
  • Do NOT use prophylactically in asymptomatic patients on immunotherapy (blunts antitumor response)
• Bevacizumab: for steroid-refractory edema or patients on immunotherapy who can't tolerate steroids
• Anticonvulsants: only if seizures occur - NOT prophylactic

Step 2: Definitive Treatment Based on Number of Mets

Step 3: Systemic Targeted Therapy - The Modern Era

---

7. LEPTOMENINGEAL / NEOPLASTIC MENINGITIS

Mechanism:

Most Common Primaries:

• Breast (especially lobular and TNBC)
• Lung (especially EGFR/ALK mutant)
• Melanoma
• Lymphoma / Leukemia

Clinical Features:

• Multifocal neurologic signs (key USMLE clue)
• Multiple cranial nerve palsies (diplopia, facial weakness, dysphagia)
• Radicular pain (from spinal nerve root involvement)
• Headache + raised ICP
• Communicating hydrocephalus

Diagnosis:

• LP with CSF cytology - gold standard (may need multiple LPs as sensitivity is ~50% on first tap)
• Gadolinium MRI spine: enhancing nodules on cauda equina / nerve roots (see spinal image below)
• Novel: circulating tumor cells in CSF or liquid biopsy

Treatment:

• Intrathecal chemotherapy (methotrexate or cytarabine via Ommaya reservoir)
• CNS-penetrant systemic agents if appropriate molecular target
• Prognosis: very poor - median survival ~6 weeks untreated, ~3-6 months with treatment

---

8. PROGNOSIS OF BRAIN METASTASES

---

9. USMLE CLASSIC QUESTION TRIGGERS

---

• Goldman-Cecil Medicine, p. 4030-4087
• Harrison's Principles of Internal Medicine 22E, p. 401-422

---

Clinical Scenario: 38F, BRCA-Negative, Post-Mastectomy + Implant, On Chemo + Radiation → Now Multiple Brain Metastases

---

FIRST: The Critical Question Before Any Plan

---

PROGNOSIS

What this presentation means:

• This is now Stage IV (metastatic) disease - a life-changing progression
• Multiple brain mets = worse prognosis than single met
• Developing brain mets during active chemo + radiation signals treatment-resistant disease
• Age 38 is independently associated with poorer outcomes (meta-analysis, PMID: 41029018)

Median Survival by Subtype with Multiple Brain Mets:

Prognostic Scoring: Breast-GPA (Graded Prognostic Assessment)

• KPS (Karnofsky Performance Status) - most important
• Number of brain mets (multiple = worse)
• Age (younger slightly better)
• ER/PR/HER2 status (HER2+ = better; TNBC = worst)
• Presence of extracranial mets

A Breast-GPA > 1 is associated with significantly improved survival after SRS (p < 0.001) - Goldman-Cecil Medicine, p. 4051; PMID: 38630386

---

IMMEDIATE MANAGEMENT PLAN

Step 1: Emergency Stabilization (Days 1-3)

---

Step 2: Definitive CNS Treatment (by number of mets)

Key: WBRT controls CNS disease but does NOT prolong overall survival - patients die of systemic disease. Hippocampal-avoidance WBRT + memantine preserves cognition (NCCTG N0179 trial). - Goldman-Cecil Medicine, p. 4061

---

Step 3: Systemic Therapy - Subtype-Driven (Most Important Step)

A. If HER2+ (Best prognosis, most options)

T-DXd (DESTINY-Breast12, PMID: 39271844): Active in both stable and active (untreated/progressing) brain mets - 12-month CNS PFS 58.9%. This is the strongest intracranial data available. Watch for: Interstitial lung disease/pneumonitis (16% incidence) - monitor with regular chest CT.

B. If ER+/PR+ / HER2- (Luminal)

Key caveat from Katzung: "Patients with significant visceral involvement of the lung, liver, or brain or those with rapidly progressive disease rarely benefit from hormonal therapies. In this setting, systemic chemotherapy is usually indicated." - Katzung, p. 363

C. If TNBC (Worst prognosis, but improving)

---

Step 4: Watch for Leptomeningeal Spread

• LP for CSF cytology (repeat if first tap negative - up to 40% false-negative rate)
• MRI brain + full spine with gadolinium
• If confirmed: intrathecal methotrexate / cytarabine via Ommaya reservoir + focal radiation to bulky/symptomatic areas

Prognosis if leptomeningeal spread: median survival 10-12 weeks untreated; up to ~3-6 months with treatment. - Harrison's Principles, p. 433

---

Step 5: Supportive Care and Multidisciplinary Team

---

DECISION ALGORITHM SUMMARY

Multiple Brain Mets in 38F Breast Ca (BRCA-)
            │
            ▼
   URGENT: Dexamethasone 8-12 mg/day
            │
            ▼
   Biopsy → Confirm ER/PR/HER2
            │
     ┌──────┼──────┐
     ▼      ▼      ▼
   HER2+   HR+   TNBC
     │      │      │
 T-DXd   CDK4/6  Pembro
 Tucatinib Fulv   + SRS
 + WBRT  + WBRT  + WBRT
     │      │      │
     └──────┴──────┘
            │
     Monitor for leptomeningeal spread
     (LP if CN palsies / radiculopathy)
            │
     Palliative care integration
     Clinical trial enrollment

---

Key Numbers to Remember

• Goldman-Cecil Medicine, p. 4049-4087
• Katzung's Basic & Clinical Pharmacology 16e, p. 361-367
• Harrison's Principles of Internal Medicine 22E, p. 401-442

---

Case Analysis: This Specific Patient

---

RECONSTRUCTED CLINICAL TIMELINE

---

CRITICAL MOLECULAR INTERPRETATION

What Subtype Is This?

ER 1% + PR- + HER2 2+/FISH- = HER2-LOW, Quasi-Triple Negative

• By standard IHC criteria: treated as Triple Negative (ER functionally negative, PR-, HER2-)
• BUT HER2 IHC 2+ / FISH- = "HER2-low" (IHC 1+ or 2+/FISH-) - a newly recognized category
• This is critical because it opens eligibility for T-DXd (trastuzumab deruxtecan), which is now approved for HER2-low metastatic breast cancer

---

WHY DID SHE DEVELOP BRAIN METS DESPITE pCR?

1. pCR in breast = no residual tumor - excellent local response to NACT
2. BUT: pCR does NOT guarantee systemic cure - micrometastases may have already seeded the brain BEFORE surgery (occult CNS disease)
3. Her tumor profile - Ki-67 84% + Oncotype 69 + Grade 3 - represents one of the most biologically aggressive breast cancer phenotypes
4. The CNS is a pharmacological sanctuary site - most chemotherapy agents do not penetrate the blood-brain barrier well
5. Brain mets appeared ~9 months post-surgery - consistent with dormant micrometastases becoming clinically evident
6. Family history (both grandmothers with breast Ca) suggests inherited/polygenic risk even though BRCA1/2 is negative

---

CURRENT STATUS ANALYSIS

Her brain lesions (MRI 27/11/2025):

• Ring-enhancing lesion, right frontal lobe (dominant)
• Small lesions, left frontal lobe parasagittal + left basifrontal cortex
• = Multiple bilateral brain metastases (at least 3 lesions identified)
• Frontal lobe location: risk of personality change, executive dysfunction, contralateral motor weakness

Performance Status:

• ECOG PS 1 - she is functional, good performance status
• This is a favorable prognostic factor for treatment eligibility and response

Restaging needed NOW:

• The PET-CT from Jan 2025 showed no systemic disease - this must be repeated to confirm there is no extracranial progression (bone, liver, lung)

---

PROGNOSIS - HONEST AND PRECISE

Estimated Median OS (brain mets, this profile):

• Without aggressive CNS + systemic treatment: ~6-9 months
• With SRS/WBRT + T-DXd: Potentially 12-20+ months based on DEBBRAH trial data
• DEBBRAH trial (PMID: 39255534): T-DXd in HER2-low active brain mets → intracranial ORR 50% (untreated mets) and 33% (post-local therapy progression), median intracranial response duration 7.2 months

This is NOT a hopeless situation. The emergence of HER2-low as a targetable category means she may benefit from T-DXd - which would NOT have been available 3 years ago.

---

MANAGEMENT PLAN - STEP BY STEP

IMMEDIATE (This Week)

---

CNS-DIRECTED TREATMENT (Primary Plan)

Preferred: SRS (Stereotactic Radiosurgery) for each identified lesion

• Rationale: ECOG 1, young, cognitive preservation critical, limited number of lesions
• SRS to right frontal lesion (dominant) + left frontal + left basifrontal = 3 lesion targets
• Growing evidence supports SRS for up to 10 lesions
• Concurrent T-DXd + SRS: 12-month local control 97%, symptomatic radiation necrosis only 2.1% per lesion (PMID: 39572568)

Alternative: Hippocampal-Avoidance WBRT + Memantine

• If SRS not available or lesion count grows on repeat MRI
• Standard: 30 Gy / 10 fractions (3 Gy/fraction)
• Add memantine to reduce cognitive decline
• BUT: avoid WBRT if planning immunotherapy - it may blunt antitumor response

---

SYSTEMIC THERAPY - THE GAME CHANGER FOR HER

She is HER2-low (IHC 2+/FISH-) → T-DXd (Trastuzumab Deruxtecan) eligible

Recommended Systemic Sequence:

First: Check PD-L1 status (CPS score on tumor/immune cells)
         │
    PD-L1+ (CPS ≥10)       PD-L1- (or not tested)
         │                          │
Pembrolizumab + chemo         T-DXd (5.4 mg/kg q21d)
+ T-DXd consideration          (HER2-low indication)
         │                          │
   Concurrent with SRS        Concurrent with SRS
         │                          │
    Monitor ILD                Monitor ILD
    (T-DXd risk 16-25%)        (CT chest q3 cycles)

Critical warning: T-DXd carries a 16-25% risk of interstitial lung disease (ILD)/pneumonitis. Must monitor with CT chest every 2-3 cycles. She previously received chest radiation (adjuvant RT to left breast) which may increase this risk. Manage proactively.

---

WATCH FOR LEPTOMENINGEAL SPREAD

• New cranial nerve palsy (diplopia, facial droop, dysphagia)
• New radicular back pain / leg weakness
• Progressive headache despite controlled brain lesions
• Hearing loss

---

SUPPORTIVE CARE

---

ONE-PAGE SUMMARY FOR WARD ROUNDS

38F | IDC Left Breast Grade 3 | Stage IIIB (T2N2b) at diagnosis
IHC: ER1% PR- HER2(2+/FISH-) = HER2-LOW | Ki-67 84% | Oncotype 69
NACT → pCR (0/5 LN) → BCS Feb 2025 → Adjuvant RT Feb-Mar 2025
→ MRI Brain Nov 2025: Multiple ring-enhancing lesions (R frontal + L frontal + L basifrontal)
→ Family Hx: Both grandmothers breast Ca | BRCA negative

PROGNOSIS: Guarded - median OS 12-20 months with aggressive Rx
KEY ADVANTAGE: HER2-low → T-DXd eligible (game-changer)

IMMEDIATE PLAN:
1. Dexamethasone 8 mg BD
2. Repeat MRI brain + PET-CT whole body + MRI spine
3. PD-L1 testing on archival or new biopsy
4. SRS to identified lesions (preferred over WBRT for cognitive preservation)
5. T-DXd 5.4 mg/kg q21d (HER2-low, brain mets)
   OR pembrolizumab + chemo if PD-L1+
6. Monitor: ILD (CT chest q3 cycles), seizures, leptomeningeal signs
7. Expand genetic panel (PALB2, ATM, CHEK2)
8. Multidisciplinary tumor board discussion

---

• Goldman-Cecil Medicine, p. 4049-4087
• Katzung's Basic & Clinical Pharmacology 16e, p. 361-367
• DEBBRAH Trial: T-DXd in HER2-low brain mets → intracranial ORR 50% (PMID: 39255534)
• T-DXd + SRS: 97% local control, low necrosis risk (PMID: 39572568)
• TNBC brain mets + SRS + pembrolizumab: median OS 23 months (PMID: 38630386)

---

ALL NEXT BEST POSSIBLE STEPS - Complete Roadmap

Patient Profile Recap

---

PHASE 1: RIGHT NOW - THIS WEEK (Days 1-7)

A. Symptom Control - Start Immediately

Begin steroid taper as soon as radiation planning starts - taper by 2 mg every 3-4 days once symptoms improve. Prolonged dexamethasone = Cushingoid features, myopathy, opportunistic infections.

---

B. Urgent Investigations to Order NOW

---

PHASE 2: RADIATION PLANNING (Week 1-2)

Decision: SRS vs. WBRT

How many lesions on repeat MRI?
        │
   ≤10 lesions          >10 lesions
        │                    │
   SRS (preferred)      HA-WBRT + Memantine
   for each lesion      (if SRS not feasible)
        │
   Can ALL lesions
   be targeted by SRS?
        │
   YES → SRS alone     NO (deeply seated/
        │               brainstem) → SRS + WBRT
   Add systemic Tx
   concurrently

Option A: SRS (Strongly Preferred for Her)

Option B: HA-WBRT + Memantine (If SRS Not Feasible)

Post-Radiation:

• Steroid taper begins immediately after completing radiation
• Monitor for radiation necrosis: MRI at 6-8 weeks post-SRS
  • Radiation necrosis vs. recurrence: use MRI perfusion, MR spectroscopy, or FDG-PET
  • If radiation necrosis confirmed: bevacizumab 7.5 mg/kg q3w × 4-6 cycles (reduces necrosis)

---

PHASE 3: SYSTEMIC THERAPY - THE CRITICAL DECISION (Start within 2-4 weeks)

Step 1: Check PD-L1 Result

If PD-L1 POSITIVE (CPS ≥10):

If PD-L1 NEGATIVE or Unknown:

T-DXd ILD Monitoring Protocol:

Before each cycle: symptom screen (new cough, dyspnea, fever)
Every 3 cycles (9 weeks): CT chest HRCT
At any new respiratory symptom: CT chest immediately

ILD Grade 1 (radiologic only):
→ Hold T-DXd, repeat CT in 3-4 weeks, resume if resolved

ILD Grade 2 (mild symptoms):
→ Hold T-DXd, start dexamethasone 0.5-1 mg/kg/day
→ Taper over ≥4 weeks, DO NOT re-challenge

ILD Grade 3-4 (severe/life-threatening):
→ PERMANENTLY DISCONTINUE T-DXd
→ High-dose IV methylprednisolone + pulmonology

---

PHASE 4: SEQUENTIAL THERAPY PLAN - LINE BY LINE

After NACT (anthracycline + taxane-based), adjuvant RT, now brain mets:

---

PHASE 5: GENOMIC TESTING AND CLINICAL TRIALS

Expand Molecular Testing NOW

Clinical Trials to Actively Seek

---

PHASE 6: SURVEILLANCE AND RESPONSE ASSESSMENT

MRI Monitoring Schedule (Post-treatment)

Pseudoprogression vs. Radiation Necrosis vs. True Progression

---

PHASE 7: LEPTOMENINGEAL METASTASIS PREPAREDNESS

• New diplopia / facial weakness / hearing change (cranial nerve involvement)
• New radicular pain / limb weakness / urinary symptoms
• Worsening headache despite controlled brain lesions
• New cognitive decline disproportionate to known lesions

1. MRI brain + full spine with gadolinium
2. LP: CSF cytology + protein + glucose + opening pressure
   • Repeat LP if 1st negative (40% false-negative rate on first tap)
   • Consider CSF liquid biopsy (ctDNA in CSF) if available
3. If confirmed leptomeningeal mets:
   • Ommaya reservoir insertion by neurosurgery
   • Intrathecal methotrexate 12 mg twice/week × 4 weeks → maintenance weekly
   • Focal RT to bulky/symptomatic areas or obstructed CSF flow sites
   • T-DXd has shown activity even in leptomeningeal disease (DEBBRAH trial leptomeningeal cohort, PMID: 39265579)
   • Prognosis with LM: 10-12 weeks without Tx; 3-6 months with Tx + targeted agent

---

PHASE 8: HOLISTIC CARE - NON-NEGOTIABLE

---

COMPLETE DECISION FLOWCHART

TODAY
  │
  ├─ START Dexamethasone 16 mg/day + PPI + LMWH
  ├─ ORDER: MRI brain full + MRI spine + PET-CT + PD-L1 + CBC/LFT/RFT + Echo + HRCT chest
  │
WEEK 1-2: MDT TUMOR BOARD
  │
  ├─ Radiation decision:
  │     ≤10 lesions → SRS (preferred, Dr Rohith DNB-RT)
  │     >10 or SRS not feasible → HA-WBRT 30Gy/10f + Memantine
  │
  ├─ Systemic therapy (start with or soon after radiation):
  │     PD-L1+ (CPS≥10) → Pembrolizumab 200 mg + Carbo + nab-Pac
  │     PD-L1- → T-DXd 5.4 mg/kg q21d (HER2-low indication)
  │
WEEK 4 ONWARDS: MONITORING
  │
  ├─ MRI brain q8-12 weeks
  ├─ CT chest q3 cycles (T-DXd ILD)
  ├─ Watch for LM signs every visit
  │
PROGRESSION ON LINE 1:
  ├─ SRS to new brain lesions (safe even repeatedly)
  ├─ Switch to: SG + SRS → then Capecitabine ± Bev → then Eribulin
  ├─ Send NGS panel, enroll clinical trial
  │
LEPTOMENINGEAL PROGRESSION:
  └─ Ommaya + Intrathecal MTX + T-DXd systemic

---

SURVIVAL EXPECTATIONS - REALISTIC AND HONEST

She has several favorable factors: ECOG PS 1, pCR in breast, minimal systemic disease (clean PET Jan 2025), HER2-low eligibility for T-DXd, young immune system for immunotherapy. These are real reasons for cautious optimism with aggressive management.

---

• Goldman-Cecil Medicine, p. 4049-4087
• Katzung's Basic & Clinical Pharmacology 16e, p. 361-367
• DEBBRAH trial - T-DXd in HER2-low + brain mets: intracranial ORR 50% (PMID: 39255534)
• SG + SRS multi-institutional: zero radiation necrosis, 94% LC at 12mo (PMID: 41026418)
• SG CNS penetration confirmed in phase 0 trial: OS 35.2 months BCBM cohort (PMID: 39112464)
• Gamma Knife safe for >20 brain lesions, targeted therapy reduces BMV (PMID: 41099786)
• TNBC brain mets systemic treatment systematic review 2025 (PMID: 40546710)

---

CONTINUATION: Complete Management - Everything Left

---

PHASE 9: EMERGING AND PIPELINE THERAPIES FOR HER PROFILE

Datopotamab Deruxtecan (Dato-DXd)

• Anti-TROP-2 ADC using the same DXd payload as T-DXd
• Phase III TROPION-Breast01: significant PFS benefit in HR+/HER2-low metastatic BC
• CNS activity being investigated; listed in emerging therapy review (PMID: 39625633) as offering "new hope" for TNBC brain mets
• Relevance to her: If T-DXd fails → Dato-DXd may be next Trop-2-directed option (different from SG)
• Advantage over SG: Less diarrhea; different toxicity profile

AKT Inhibitors (Capivasertib, Ipatasertib)

• PIK3CA/AKT/PTEN pathway activated in ~30-40% of TNBC
• Capivasertib + fulvestrant: approved for HR+/HER2- with PIK3CA/AKT/PTEN alteration
• If her NGS panel shows PTEN loss or AKT activation → consider capivasertib
• CNS penetration data emerging

PARP Inhibitors (Even Without BRCA1/2)

• If expanded panel shows PALB2, RAD51C/D, or ATM mutation → olaparib or talazoparib eligible
• Talazoparib: active in TNBC brain mets in preliminary data (included in DEBBRAH protocol)
• Critical to check expanded germline panel - this is a potentially missed opportunity

Immunotherapy Combinations

• Nivolumab + ipilimumab (dual checkpoint): active in TNBC brain mets in trials
• Atezolizumab (anti-PD-L1): IMpassion130 showed benefit in PD-L1+ TNBC but note: different assay from pembrolizumab (SP142 vs. 22C3) - results not interchangeable
• Pembrolizumab remains preferred based on KEYNOTE-522 data

Blood-Brain Barrier Disruption Strategies (Emerging)

• Focused ultrasound (MRgFUS) to open BBB focally → allows systemic drugs to penetrate CNS better
• Mannitol IV transiently opens BBB - used before intrathecal therapy
• Not standard yet but being studied in clinical trials

---

PHASE 10: DRUG DOSING REFERENCE CARD (For Daily Clinical Use)

Dexamethasone Taper Protocol (Post-Radiation)

Starting dose: 8 mg BD (16 mg/day)
Week 1-2 (during radiation): Maintain 16 mg/day
Week 3: 8 mg morning + 4 mg evening (12 mg/day)
Week 4: 4 mg BD (8 mg/day)
Week 5: 4 mg morning + 2 mg evening (6 mg/day)
Week 6: 4 mg OD morning (4 mg/day)
Week 7: 2 mg OD morning (2 mg/day)
Week 8: 1 mg OD → then STOP

If symptoms return at any step: increase to previous dose, hold taper for 1 week
Always co-prescribe: Omeprazole 20 mg OD throughout steroid use
Consider Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis if on steroids >4 weeks

T-DXd Protocol

Dose: 5.4 mg/kg IV over 90 min (first infusion) → 30 min if tolerated
Cycle: Every 21 days
Pre-medications: Antiemetics (ondansetron + dexamethasone 8 mg) 30 min before
Day 1: Infusion
Day 2-21: Monitor for ILD symptoms daily (patient to report any new cough/dyspnea/fever)

Dose reductions:
Level -1: 4.4 mg/kg
Level -2: 3.2 mg/kg
(Maximum 2 dose reductions; then discontinue if further reduction needed)

ILD monitoring:
- Baseline HRCT chest before cycle 1
- HRCT chest every 3 cycles (day 1 of cycles 4, 7, 10...)
- Immediate CT if ANY respiratory symptom

Sacituzumab Govitecan (SG) Protocol

Dose: 10 mg/kg IV days 1 and 8 of 21-day cycle
Pre-meds: Antiemetics + atropine (for cholinergic diarrhea with first dose)
Key toxicities to monitor:
- Neutropenia (Grade 3-4 in ~28%): CBC weekly for first 2 cycles, then day 1 and 8
- Diarrhea: Loperamide 4 mg at onset, then 2 mg after every loose stool; max 16 mg/day
- Alopecia: Expected and reversible
- UGT1A1*28 genotyping: If homozygous *28/*28 → higher SN-38 exposure → increased toxicity risk → consider dose reduction to 7.5 mg/kg

Pembrolizumab Protocol

Dose: 200 mg IV q21d (fixed dose) OR 400 mg q42d (maintenance)
Duration: Until progression, intolerable toxicity, or 2 years (whichever first)
Key immune-related adverse events (irAEs) to monitor:
- Pneumonitis: Dyspnea, new cough → CT chest → hold if G2, stop if G3-4
- Colitis: Diarrhea >4 stools/day → hold, steroids if G2+
- Hepatitis: LFT every cycle → hold if AST/ALT >3x ULN
- Endocrinopathy: Hypothyroidism (most common), adrenal insufficiency → TSH, cortisol q3 cycles
- Neurologic: Encephalitis, meningitis → VERY important in this patient with brain mets - any new confusion → brain MRI + LP

Note: Immunotherapy + WBRT → blunts immune response; use SRS preferentially with pembro

Memantine (with HA-WBRT)

Week 1: 5 mg OD
Week 2: 5 mg BD
Week 3: 5 mg AM + 10 mg PM
Week 4 onwards: 10 mg BD (target dose)
Duration: Continue for 6 months post-WBRT
Mechanism: NMDA receptor antagonist → prevents glutamate excitotoxicity from radiation

---

PHASE 11: TOXICITY MANAGEMENT - COMMON SCENARIOS

Scenario 1: Steroid Complications (Very Likely)

Scenario 2: Radiation Toxicity Post-SRS

Scenario 3: T-DXd Interstitial Lung Disease

Grade 1: Asymptomatic, radiologic only
→ Hold T-DXd
→ Repeat CT in 3-4 weeks
→ If resolved: resume at same dose (with caution)
→ If not resolved: treat as Grade 2

Grade 2: Mild/moderate symptoms, limiting ADLs
→ HOLD T-DXd PERMANENTLY
→ Prednisolone 1 mg/kg/day PO
→ Taper over minimum 4 weeks
→ Pulmonology referral
→ Do NOT rechallenge

Grade 3: Severe, requiring oxygen
→ Hospitalize
→ IV methylprednisolone 1-2 mg/kg/day
→ Taper over 6+ weeks
→ PERMANENTLY DISCONTINUE T-DXd
→ Consider IVIG/mycophenolate if steroid-refractory

Grade 4: Life-threatening
→ ICU
→ High-dose IV steroids
→ Intubation if needed
→ Fatal in ~1-2% of cases

Scenario 4: Worsening Brain Mets During Treatment

---

PHASE 12: COMMUNICATION AND COUNSELLING GUIDE

How to Talk to This Patient

• "The cancer has spread to the brain - this is serious but not untreatable."
• "We have specific treatments that work in the brain - radiation directly to these spots, and new medicines that can cross into the brain."
• "Your profile - the way your cancer cells look - actually opens a newer drug called T-DXd that specifically targets your tumor type."
• "Our goal right now is to control this in your brain AND throughout your body, while keeping your quality of life as good as possible."
• "We will monitor you every 2-3 months with MRI and scans so we always know exactly what is happening."

• "There is nothing more we can do." - FALSE. There are multiple active lines of therapy.
• "You have X months to live." - Population statistics do NOT apply to individuals, especially with new agents.
• "This treatment will cure you." - Metastatic breast cancer is currently incurable, but long-term control is real and increasing.

Goals of Care Conversation (Must Happen Early)

---

PHASE 13: BONE HEALTH AND SYSTEMIC COMPLICATION PREVENTION

---

PHASE 14: ONCOLOGICAL EMERGENCIES TO ANTICIPATE AND PREVENT

---

PHASE 15: THE 3-MONTH ROADMAP - TIMELINE

WEEK 1-2
├─ Dexamethasone 16 mg/day + PPI + LMWH
├─ Repeat MRI brain (full protocol, gadolinium)
├─ MRI spine (gadolinium)
├─ PET-CT whole body
├─ PD-L1 testing (CPS on archival block)
├─ Baseline bloods: CBC, LFT, RFT, glucose, Ca²⁺, LDH, CA 15-3
├─ Echo + HRCT chest (baseline pre-T-DXd)
├─ Expanded germline gene panel (PALB2, ATM, CHEK2 etc.)
└─ MDT Tumor Board

WEEK 2-3
├─ RADIATION PLANNING SESSION
│   └─ SRS simulation CT + MRI fusion
│       → Treatment plan computed (1-3 days)
│       → SRS delivered (1-3 sessions for multiple targets)
└─ Start steroid taper plan post-RT

WEEK 3-4
├─ Systemic therapy STARTS
│   ├─ PD-L1+: Pembrolizumab + nab-Pac + Carboplatin
│   └─ PD-L1-: T-DXd 5.4 mg/kg IV (cycle 1, day 1)
└─ Patient education: ILD symptoms, neutropenia, when to call

WEEK 6-8
├─ MRI brain: First post-SRS response assessment
├─ Cycle 2/3 bloods: CBC, LFT, glucose
├─ CT chest HRCT (T-DXd ILD check)
├─ Dexamethasone at 4 mg OD by now (taper ongoing)
└─ Palliative care team formal introduction

WEEK 12 (3 MONTHS)
├─ MRI brain: Full response assessment
├─ PET-CT or CT CAP: Systemic disease reassessment
├─ MDT review: Continue current line? Switch? New trial?
├─ CA 15-3, CEA trends
├─ Bone density DXA (if not done)
├─ Neuropsychology assessment
└─ Goals of care review

ONGOING (every cycle)
├─ Symptom review + neuro exam
├─ Drug toxicity screen
├─ BMV (brain metastasis velocity) tracking
└─ Clinical trial eligibility re-assessment each line

---

COMPLETE DRUG TOXICITY MONITORING TABLE

---

KEY NUMBERS SUMMARY FOR WARD ROUNDS

---

FINAL SUMMARY: THE 5 MOST IMPORTANT DECISIONS FOR THIS PATIENT

1. SRS (not WBRT) → Protect cognition in a 38-year-old
   ↓
2. T-DXd (HER2-low indication) OR Pembrolizumab (if PD-L1+)
   → Game-changing systemic option; intracranial activity proven
   ↓
3. MONITOR FOR ILD AGGRESSIVELY
   → Prior chest RT + T-DXd = highest risk combination
   → CT chest every 3 cycles non-negotiable
   ↓
4. WATCH FOR LEPTOMENINGEAL SPREAD
   → Quasi-TNBC = highest risk subtype
   → Low threshold to do LP + spine MRI
   ↓
5. EARLY PALLIATIVE CARE + GOALS OF CARE
   → Not giving up - improves survival AND quality of life
   → Done alongside aggressive treatment

• Goldman-Cecil Medicine, p. 4049-4087
• Katzung's Basic & Clinical Pharmacology 16e, p. 361-367
• Emerging therapies review - SG, Dato-DXd, BBB strategies (PMID: 39625633)
• Optimal therapy sequencing in metastatic BC - ASCO 2025 (PMID: 40367401)
• TNBC brain mets systemic treatment systematic review (PMID: 40546710)
• GKRS safe and effective for >20 breast Ca brain lesions (PMID: 41099786)

---

COMPLETE CASE SUMMARY AND FULL TREATMENT PLAN

Carcinoma Left Breast with Brain Metastases - 38-Year-Old Female

---

SECTION 1: PATIENT PROFILE AT A GLANCE

---

SECTION 2: FULL DISEASE HISTORY - TIMELINE

2.1 Original Diagnosis (August-October 2024)

2.2 Neoadjuvant Chemotherapy (NACT) - Oct 2024 to Feb 2025

2.3 Surgery (February 2025)

2.4 Adjuvant Radiotherapy (Feb-Mar 2025)

• Adjuvant RT to left breast / chest wall completed as per plan
• Consultant: Dr. Rohith S, DNB(RT)

2.5 Brain Metastases Discovered (November 2025)

---

SECTION 3: MOLECULAR BIOLOGY - DECODING HER TUMOR

3.1 IHC Interpretation

3.2 What Subtype Is This?

ER 1% (functionally negative) + PR- + HER2 (2+/FISH-) =

Standard Classification: TRIPLE NEGATIVE BREAST CANCER (TNBC)
But critically: HER2 IHC 2+ / FISH- = "HER2-LOW" category

3.3 Why Did She Develop Brain Mets Despite pCR?

1. pCR = no residual tumor in breast - excellent local response
2. Brain = pharmacological sanctuary - most chemo does NOT cross the blood-brain barrier
3. Micrometastatic seeding happened BEFORE surgery - cells were already in brain as dormant micrometastases
4. Ki-67 84% + Grade 3 = extremely aggressive tumor with early systemic spread tendency
5. The internal mammary lymph nodes (N2b) were involved at diagnosis - this drainage route leads directly toward the CNS vasculature
6. Frontal lobe is particularly susceptible - large perfusion territory, grey-white junction traps tumor emboli

---

SECTION 4: WHAT IS HER PROGNOSIS?

4.1 Prognostic Factors Summary

4.2 Breast-GPA Score (Graded Prognostic Assessment for Brain Mets)

4.3 Realistic Survival Estimates

Real-world T-DXd data (PMID: 40691796): In HER2-low active brain mets, intracranial ORR 66.7%, 12-month OS rate 85.7% - this is encouraging data published July 2025.

Important: These are population medians. Individual responses vary enormously. Patients with ECOG PS 1, limited extracranial disease, and targetable biology (like her) can substantially exceed median survival figures.

---

SECTION 5: ALL TREATMENT OPTIONS - COMPLETE

5.1 CNS-DIRECTED TREATMENT OPTIONS

Option A: Stereotactic Radiosurgery (SRS) - PREFERRED

Option B: Hippocampal-Avoidance WBRT + Memantine

Option C: Surgery (Neurosurgical Resection)

Option D: Laser Interstitial Thermal Therapy (LITT)

• Minimally invasive ablation via laser probe - for deep/eloquent lesions not amenable to SRS
• Growing evidence but not yet standard

---

5.2 SYSTEMIC THERAPY OPTIONS - ALL LINES

STEP 1: Critical Biomarker Results Needed Before Starting

---

LINE 1 OPTIONS (Choose based on PD-L1 result):

Note: T-DXd + pembrolizumab combination is being studied in trials and may offer additive benefit - discuss at MDT.

---

LINE 2: After Line 1 Failure

---

LINE 3: After Line 2 Failure

---

LINE 4: After Line 3 Failure

---

IF NGS PANEL SHOWS ACTIONABLE MUTATION:

---

EMERGING AGENTS (Clinical Trial / Near-Approval):

---

5.3 LEPTOMENINGEAL METASTASIS TREATMENT (if it develops)

---

SECTION 6: STEP-BY-STEP TREATMENT PLAN

Phase 1: THIS WEEK (Days 1-7)

┌─────────────────────────────────────────────────┐
│ IMMEDIATE ACTIONS                                │
├──────────────────────────┬──────────────────────┤
│ Dexamethasone            │ 8 mg BD (16 mg/day)  │
│ Omeprazole               │ 20 mg OD             │
│ LMWH (enoxaparin)        │ Prophylactic SC      │
│ Blood glucose monitoring │ Daily fasting + 2hr  │
│ Levetiracetam            │ ONLY if seizures      │
└──────────────────────────┴──────────────────────┘

INVESTIGATIONS TO ORDER:
✓ MRI Brain full protocol + gadolinium (updated baseline)
✓ MRI Full Spine + gadolinium (rule out leptomeningeal)
✓ PET-CT Whole Body (restage from Jan 2025)
✓ PD-L1 testing (CPS) on archival tumor block - URGENT
✓ Expanded germline panel (PALB2, ATM, CHEK2, RAD51C/D)
✓ Full NGS panel (Foundation Medicine / similar)
✓ Baseline: CBC, LFT, RFT, LDH, Ca²⁺, CA 15-3, CEA
✓ Echocardiogram (pre-T-DXd cardiac baseline)
✓ HRCT Chest (pre-T-DXd ILD baseline)
✓ UGT1A1 genotyping (pre-SG dosing)

Phase 2: MDT TUMOR BOARD (Week 2)

• SRS simulation and planning (if ≤10 lesions on repeat MRI)
• Systemic agent selection (T-DXd vs. pembrolizumab based on PD-L1)
• Timing of systemic therapy relative to radiation
• Need for neurosurgical biopsy of dominant lesion

Phase 3: RADIATION (Week 2-3)

PREFERRED: SRS to each identified lesion
├─ Right frontal lesion (dominant) → single/fractionated SRS
├─ Left frontal parasagittal lesion → SRS
└─ Left basifrontal cortex lesion → SRS

Doses:
├─ ≤2 cm: 24 Gy single fraction
├─ 2-3 cm: 18 Gy single fraction OR 25-27 Gy/5 fractions
└─ Near eloquent cortex: 25-30 Gy/5 fractions (fSRS)

IF >10 lesions on repeat MRI OR SRS not feasible:
└─ HA-WBRT 30 Gy/10 fractions + Memantine 10 mg BD × 6 months

Begin STEROID TAPER immediately after last radiation session

Phase 4: SYSTEMIC THERAPY (Week 3-4, concurrent or immediately after SRS)

PD-L1 CPS ≥10 → Pembrolizumab 200 mg q21d
                + Nab-paclitaxel 100 mg/m² days 1,8,15
                + Carboplatin AUC2 days 1,8

PD-L1 CPS <10 → T-DXd 5.4 mg/kg IV q21d
  (HER2-low indication - approved)

MONITORING ON T-DXd:
├─ Pre-infusion: CBC, LFT, RFT every cycle
├─ Symptom screen every cycle (cough, dyspnea, fever = STOP)
└─ HRCT Chest: Baseline, then every 3 cycles (cycles 4,7,10...)

MONITORING ON PEMBROLIZUMAB:
├─ TSH, LFT, glucose, creatinine every cycle
└─ Any new confusion/headache = differentiate from tumor vs. encephalitis

Phase 5: RESPONSE ASSESSMENT (Week 8-12)

Week 6-8 post-SRS:
├─ MRI Brain + gadolinium → First CNS response assessment
│  └─ Enlargement at this point = LIKELY PSEUDOPROGRESSION
│     → Do NOT change therapy; repeat MRI in 4-6 weeks
└─ CT CAP → Systemic disease assessment

Week 12 (3-month mark):
├─ MRI Brain (full response by RANO-BM criteria)
├─ PET-CT or CT CAP (systemic)
├─ CA 15-3 trend
└─ MDT review: Continue? Switch? New trial?

Every visit (ongoing):
├─ Neuro exam (frontal lobe function - cognition, personality, motor)
├─ Screen for leptomeningeal signs (CN palsies, radiculopathy)
└─ BMV (brain metastasis velocity) tracking

Phase 6: PROGRESSION MANAGEMENT

NEW brain lesions while on systemic therapy:
├─ SRS to new lesion(s) - safe repeatedly
└─ Reassess systemic therapy - switch if multiple new lesions

SYSTEMIC PROGRESSION:
└─ Move to next systemic line (SG → Cap/Bev → Eribulin → Trial)

RADIATION NECROSIS (confirmed by perfusion MRI):
└─ Bevacizumab 7.5 mg/kg q3w × 4-6 cycles

LEPTOMENINGEAL PROGRESSION (CN palsy / radiculopathy):
├─ LP for CSF cytology (repeat if 1st negative)
├─ MRI full spine
└─ Ommaya reservoir + intrathecal MTX + continue T-DXd

---

SECTION 7: COMPLETE DRUG MONITORING CARD

---

SECTION 8: EMERGENCY PROTOCOLS

---

SECTION 9: HOLISTIC AND SUPPORTIVE CARE

Non-Negotiable Referrals

Bone Health (Proactive)

• DXA scan (baseline bone density) - she has had chemo + steroids + likely chemotherapy-induced menopause
• Calcium 500 mg BD + Vitamin D 1000 IU OD
• If bone mets confirmed on PET-CT: zoledronic acid 4 mg IV q4 weeks (after dental clearance)

Steroid Side Effect Prevention

GI protection: Omeprazole 20 mg OD throughout
Infection prevention: TMP-SMX 1 DS tab 3x/week if on steroids >4 weeks + lymphopenia
Bone protection: Ca + Vit D + weekly alendronate if on steroids >3 months
Glucose: Monitor fasting daily; consider metformin or insulin if >200 mg/dL
Mood/sleep: Give all steroids in morning; melatonin if insomnia

---

SECTION 10: GOALS OF CARE AND COMMUNICATION

• Her cancer has spread to the brain - serious but actively treatable
• Her tumor has a specific feature (HER2-low) that makes her eligible for a newer, targeted drug (T-DXd) that works directly in the brain
• The goal is to control the cancer in the brain and throughout the body while maintaining quality of life
• She will be monitored with MRI every 2-3 months
• There are multiple lines of treatment available - we are not at the end of options

• What matters most to her in daily life right now?
• What does she want to be able to do / be present for?
• Who is her healthcare decision-maker if she cannot speak for herself?
• Does she want advance directives documented?

---

SECTION 11: 3-MONTH MASTER TIMELINE

WEEK 1    ├── Dexamethasone + PPI + LMWH started
          ├── All investigations ordered (MRI, PET-CT, PD-L1, NGS, bloods)
          └── Palliative care + neuropsychology referrals made

WEEK 2    ├── MDT Tumor Board (all specialties)
          └── Radiation simulation CT + MRI fusion planning

WEEK 3    ├── SRS delivered to all identifiable lesions
          └── Steroid taper initiated

WEEK 4    ├── Systemic therapy starts:
          │     T-DXd 5.4 mg/kg q21d (HER2-low)
          │     OR Pembro + Carbo + nab-Pac (PD-L1+)
          └── Patient education: ILD symptoms, when to call emergency

WEEK 6-8  ├── MRI Brain: First post-SRS assessment
          ├── CT Chest HRCT (T-DXd cycle 3 ILD check)
          ├── Cycle bloods
          └── Dexamethasone at 4 mg OD or off by now

WEEK 12   ├── Full MRI Brain response (RANO-BM)
          ├── PET-CT whole body restaging
          ├── CA 15-3, CEA trend
          ├── Neuropsychology assessment
          └── MDT Review: Continue? Switch? Trial?

ONGOING   ├── MRI Brain every 8-12 weeks
          ├── CT CAP every 3-4 months
          ├── CT Chest every 3 cycles (T-DXd)
          └── Leptomeningeal surveillance every visit

---

SECTION 12: THE BOTTOM LINE

THIS PATIENT HAS:
✗ Stage IV disease (incurable in current medicine)
✓ ECOG PS 1 - she is functional and fit for aggressive treatment
✓ pCR achieved - her tumor responded beautifully to NACT
✓ Clean systemic staging (no liver/lung/bone mets documented)
✓ HER2-low status (IHC 2+/FISH-) = T-DXd eligible
✓ Multiple active systemic therapy lines available
✓ Young immune system = better immunotherapy response
✓ Frontal lobe mets = accessible to SRS
✓ Active clinical trials available for her profile

BEST POSSIBLE OUTCOME WITH AGGRESSIVE MANAGEMENT:
→ SRS achieves local CNS control (97% at 12 months)
→ T-DXd achieves intracranial + systemic response (ORR 50-67%)
→ 12-month OS rate: 85.7% in HER2-low brain mets cohort
→ Median OS: 15-24+ months (potentially longer with newer agents)

THE 5 MOST IMPORTANT DECISIONS:
1. SRS over WBRT → preserve cognition at age 38
2. T-DXd (HER2-low) over standard chemo → 50-67% intracranial ORR
3. Check PD-L1 → may open pembrolizumab with further benefit
4. Monitor aggressively for ILD (prior chest RT = higher risk)
5. Watch for leptomeningeal spread every single visit

---

• Goldman-Cecil Medicine, p. 4049-4087
• Schwartz's Principles of Surgery 11e, p. 1228-1230
• Katzung's Basic & Clinical Pharmacology 16e, p. 361-367
• Real-world T-DXd in HER2-low active brain mets: iORR 66.7%, 12-month OS 85.7% (PMID: 40691796)
• DEBBRAH trial - T-DXd in HER2-low brain mets: intracranial ORR 50% (PMID: 39255534)
• SRS + T-DXd: 97% LC, 2.1% necrosis (PMID: 39572568)
• SRS + SG: 94% LC, 0% necrosis (PMID: 41026418)
• TNBC brain mets + SRS + pembrolizumab: median OS 23 months (PMID: 38630386)